JP2018520642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520642A5 JP2018520642A5 JP2017557140A JP2017557140A JP2018520642A5 JP 2018520642 A5 JP2018520642 A5 JP 2018520642A5 JP 2017557140 A JP2017557140 A JP 2017557140A JP 2017557140 A JP2017557140 A JP 2017557140A JP 2018520642 A5 JP2018520642 A5 JP 2018520642A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 70
- 239000003814 drug Substances 0.000 claims 24
- 210000004027 cell Anatomy 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 9
- 125000005647 linker group Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 102100034845 KiSS-1 receptor Human genes 0.000 claims 6
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000011800 void material Substances 0.000 claims 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 5
- -1 MMP -8 Proteins 0.000 claims 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 108010023729 Complement 3d Receptors Proteins 0.000 claims 4
- 102000011412 Complement 3d Receptors Human genes 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 4
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 4
- 101001091205 Homo sapiens KiSS-1 receptor Proteins 0.000 claims 4
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims 4
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims 4
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 claims 4
- 102000035195 Peptidases Human genes 0.000 claims 4
- 108091005804 Peptidases Proteins 0.000 claims 4
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229940088598 enzyme Drugs 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 3
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 3
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims 3
- 102000005741 Metalloproteases Human genes 0.000 claims 3
- 108010006035 Metalloproteases Proteins 0.000 claims 3
- 102100023123 Mucin-16 Human genes 0.000 claims 3
- 102100038437 Sodium-dependent phosphate transport protein 2B Human genes 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000012642 immune effector Substances 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 2
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 2
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims 2
- 102100024220 CD180 antigen Human genes 0.000 claims 2
- 108090000426 Caspase-1 Proteins 0.000 claims 2
- 102100035904 Caspase-1 Human genes 0.000 claims 2
- 102100024940 Cathepsin K Human genes 0.000 claims 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 2
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 2
- 101710109241 E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 claims 2
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 102000001398 Granzyme Human genes 0.000 claims 2
- 108060005986 Granzyme Proteins 0.000 claims 2
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 2
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 claims 2
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 2
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 claims 2
- 101000958332 Homo sapiens Lymphocyte antigen 6 complex locus protein G6d Proteins 0.000 claims 2
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 claims 2
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims 2
- 101000829779 Homo sapiens Probable G-protein coupled receptor 19 Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101000825475 Homo sapiens Protein shisa-2 homolog Proteins 0.000 claims 2
- 101000604039 Homo sapiens Sodium-dependent phosphate transport protein 2B Proteins 0.000 claims 2
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 claims 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 claims 2
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 claims 2
- 102000052922 Large Neutral Amino Acid-Transporter 1 Human genes 0.000 claims 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 2
- 102100038210 Lymphocyte antigen 6 complex locus protein G6d Human genes 0.000 claims 2
- 101710112577 Multidrug resistance protein 4 Proteins 0.000 claims 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 2
- 102100023417 Probable G-protein coupled receptor 19 Human genes 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100022938 Protein shisa-2 homolog Human genes 0.000 claims 2
- 108091006232 SLC7A5 Proteins 0.000 claims 2
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 102100031228 Transient receptor potential cation channel subfamily M member 4 Human genes 0.000 claims 2
- 102000003425 Tyrosinase Human genes 0.000 claims 2
- 108060008724 Tyrosinase Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001640 apoptogenic effect Effects 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 210000004901 leucine-rich repeat Anatomy 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 235000019833 protease Nutrition 0.000 claims 2
- 235000019419 proteases Nutrition 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091007507 ADAM12 Proteins 0.000 claims 1
- 108091007505 ADAM17 Proteins 0.000 claims 1
- 108091005663 ADAMTS5 Proteins 0.000 claims 1
- 102000051389 ADAMTS5 Human genes 0.000 claims 1
- 102100025261 AMSH-like protease Human genes 0.000 claims 1
- 101710195537 AMSH-like protease Proteins 0.000 claims 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 101710129514 B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 108010003455 BLyS receptor Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010085074 Brevican Proteins 0.000 claims 1
- 102100032312 Brevican core protein Human genes 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 108010032088 Calpain Proteins 0.000 claims 1
- 102000007590 Calpain Human genes 0.000 claims 1
- 102000003900 Calpain-2 Human genes 0.000 claims 1
- 108090000232 Calpain-2 Proteins 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 102000004018 Caspase 6 Human genes 0.000 claims 1
- 108090000425 Caspase 6 Proteins 0.000 claims 1
- 108090000567 Caspase 7 Proteins 0.000 claims 1
- 102000004066 Caspase-12 Human genes 0.000 claims 1
- 108090000570 Caspase-12 Proteins 0.000 claims 1
- 102000004958 Caspase-14 Human genes 0.000 claims 1
- 108090001132 Caspase-14 Proteins 0.000 claims 1
- 102000004046 Caspase-2 Human genes 0.000 claims 1
- 108090000552 Caspase-2 Proteins 0.000 claims 1
- 102100029855 Caspase-3 Human genes 0.000 claims 1
- 102100025597 Caspase-4 Human genes 0.000 claims 1
- 101710090338 Caspase-4 Proteins 0.000 claims 1
- 102100038916 Caspase-5 Human genes 0.000 claims 1
- 101710090333 Caspase-5 Proteins 0.000 claims 1
- 102100038902 Caspase-7 Human genes 0.000 claims 1
- 102000004091 Caspase-8 Human genes 0.000 claims 1
- 108090000538 Caspase-8 Proteins 0.000 claims 1
- 102100026550 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 108010059081 Cathepsin A Proteins 0.000 claims 1
- 102000005572 Cathepsin A Human genes 0.000 claims 1
- 108090000712 Cathepsin B Proteins 0.000 claims 1
- 102000004225 Cathepsin B Human genes 0.000 claims 1
- 102000003908 Cathepsin D Human genes 0.000 claims 1
- 108090000258 Cathepsin D Proteins 0.000 claims 1
- 102000004178 Cathepsin E Human genes 0.000 claims 1
- 108090000611 Cathepsin E Proteins 0.000 claims 1
- 108090000610 Cathepsin F Proteins 0.000 claims 1
- 102000004176 Cathepsin F Human genes 0.000 claims 1
- 108090000619 Cathepsin H Proteins 0.000 claims 1
- 102000004175 Cathepsin H Human genes 0.000 claims 1
- 108090000625 Cathepsin K Proteins 0.000 claims 1
- 108090000624 Cathepsin L Proteins 0.000 claims 1
- 102000004172 Cathepsin L Human genes 0.000 claims 1
- 102100026540 Cathepsin L2 Human genes 0.000 claims 1
- 101710169274 Cathepsin L2 Proteins 0.000 claims 1
- 101710177066 Cathepsin O Proteins 0.000 claims 1
- 108090000613 Cathepsin S Proteins 0.000 claims 1
- 102100035654 Cathepsin S Human genes 0.000 claims 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 claims 1
- 102100027995 Collagenase 3 Human genes 0.000 claims 1
- 108050005238 Collagenase 3 Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100030886 Complement receptor type 1 Human genes 0.000 claims 1
- 206010054002 Congenital syphilitic osteochondritis Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 101800001224 Disintegrin Proteins 0.000 claims 1
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 claims 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108050001154 Glypican Proteins 0.000 claims 1
- 102000010956 Glypican Human genes 0.000 claims 1
- 108050007237 Glypican-3 Proteins 0.000 claims 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 102000004989 Hepsin Human genes 0.000 claims 1
- 108090001101 Hepsin Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 claims 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101100119857 Homo sapiens FCRL2 gene Proteins 0.000 claims 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 claims 1
- 101001008922 Homo sapiens Kallikrein-11 Proteins 0.000 claims 1
- 101001091379 Homo sapiens Kallikrein-5 Proteins 0.000 claims 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 claims 1
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 claims 1
- 101001038505 Homo sapiens Ly6/PLAUR domain-containing protein 1 Proteins 0.000 claims 1
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 claims 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 claims 1
- 101000853730 Homo sapiens RING finger and transmembrane domain-containing protein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000832248 Homo sapiens STAM-binding protein Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 claims 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims 1
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 claims 1
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 102000001399 Kallikrein Human genes 0.000 claims 1
- 108060005987 Kallikrein Proteins 0.000 claims 1
- 102100027612 Kallikrein-11 Human genes 0.000 claims 1
- 102100034868 Kallikrein-5 Human genes 0.000 claims 1
- 102100034866 Kallikrein-6 Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 claims 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 claims 1
- 102100040284 Ly6/PLAUR domain-containing protein 1 Human genes 0.000 claims 1
- 101710157879 Lymphocyte antigen 6E Proteins 0.000 claims 1
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 claims 1
- 102100030417 Matrilysin Human genes 0.000 claims 1
- 108090000855 Matrilysin Proteins 0.000 claims 1
- 108010091175 Matriptase Proteins 0.000 claims 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 claims 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 102100025096 Mesothelin Human genes 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 claims 1
- 101100182721 Mus musculus Ly6e gene Proteins 0.000 claims 1
- 101000623899 Mus musculus Mucin-13 Proteins 0.000 claims 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100034869 Plasma kallikrein Human genes 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 102000016611 Proteoglycans Human genes 0.000 claims 1
- 108010067787 Proteoglycans Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108010080192 Purinergic Receptors Proteins 0.000 claims 1
- 102000000033 Purinergic Receptors Human genes 0.000 claims 1
- 102100035928 RING finger and transmembrane domain-containing protein 2 Human genes 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102000014400 SH2 domains Human genes 0.000 claims 1
- 108050003452 SH2 domains Proteins 0.000 claims 1
- 108091058557 SILV Proteins 0.000 claims 1
- 108091006576 SLC34A2 Proteins 0.000 claims 1
- 102100024472 STAM-binding protein Human genes 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 101710108790 Stromelysin-1 Proteins 0.000 claims 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 102000003618 TRPM4 Human genes 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 102000002938 Thrombospondin Human genes 0.000 claims 1
- 108060008245 Thrombospondin Proteins 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 102100026159 Tomoregulin-1 Human genes 0.000 claims 1
- 102100026160 Tomoregulin-2 Human genes 0.000 claims 1
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 241000269368 Xenopus laevis Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000000576 arachnoid Anatomy 0.000 claims 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 108010018550 caspase 13 Proteins 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 102000052502 human ELANE Human genes 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 108010047374 matriptase 2 Proteins 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 108091007169 meprins Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229940012957 plasmin Drugs 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 108010037277 thymic shared antigen-1 Proteins 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021148459A JP2022023031A (ja) | 2015-05-01 | 2021-09-13 | マスク抗ｃｄ３抗体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155723P | 2015-05-01 | 2015-05-01 | |
| US62/155,723 | 2015-05-01 | ||
| PCT/US2016/030127 WO2016179003A1 (en) | 2015-05-01 | 2016-04-29 | Masked anti-cd3 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148459A Division JP2022023031A (ja) | 2015-05-01 | 2021-09-13 | マスク抗ｃｄ３抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520642A JP2018520642A (ja) | 2018-08-02 |
| JP2018520642A5 true JP2018520642A5 (https=) | 2019-06-13 |
Family
ID=56072419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557140A Pending JP2018520642A (ja) | 2015-05-01 | 2016-04-29 | マスク抗ｃｄ３抗体及びその使用方法 |
| JP2021148459A Pending JP2022023031A (ja) | 2015-05-01 | 2021-09-13 | マスク抗ｃｄ３抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148459A Pending JP2022023031A (ja) | 2015-05-01 | 2021-09-13 | マスク抗ｃｄ３抗体及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180057593A1 (https=) |
| EP (2) | EP3778640A1 (https=) |
| JP (2) | JP2018520642A (https=) |
| CN (1) | CN107709363A (https=) |
| HK (2) | HK1252158A1 (https=) |
| WO (1) | WO2016179003A1 (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| BR112014004168A2 (pt) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
| EP2904016B1 (en) | 2012-10-08 | 2018-11-14 | Roche Glycart AG | Fc-free antibodies comprising two fab-fragments and methods of use |
| MX375359B (es) | 2013-02-26 | 2025-03-06 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de células t. |
| CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| JP6464255B2 (ja) | 2014-08-04 | 2019-02-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｔ細胞活性化抗原結合分子 |
| KR20170066421A (ko) | 2014-09-12 | 2017-06-14 | 제넨테크, 인크. | 항-cll-1 항체 및 면역접합체 |
| SI3221357T1 (sl) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
| DK3221355T3 (da) | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| WO2016182064A1 (ja) | 2015-05-13 | 2016-11-17 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| TWI731861B (zh) | 2015-06-16 | 2021-07-01 | 美商建南德克公司 | FcRH5之人源化及親和力成熟抗體及使用方法 |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3356410B1 (en) | 2015-10-02 | 2021-10-20 | F. Hoffmann-La Roche AG | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
| EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
| JP6949030B2 (ja) | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| HRP20230528T1 (hr) | 2016-03-22 | 2023-08-04 | F. Hoffmann - La Roche Ag | Bispecifične molekule t stanica aktivirane proteazom |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| CN116987189A (zh) | 2016-05-20 | 2023-11-03 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP3544629A4 (en) | 2016-11-23 | 2020-06-17 | Harpoon Therapeutics, Inc. | PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF |
| CN110198955A (zh) | 2016-11-23 | 2019-09-03 | 哈普恩治疗公司 | 前列腺特异性膜抗原结合蛋白质 |
| WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| TWI797097B (zh) | 2016-11-28 | 2023-04-01 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| EP3619238A4 (en) * | 2017-05-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | CYTOTOXICITY INDUCING THERAPEUTIC |
| EP3619234A4 (en) * | 2017-05-03 | 2021-05-26 | Harpoon Therapeutics, Inc. | COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPIES |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| CN111278461A (zh) | 2017-08-16 | 2020-06-12 | 百时美施贵宝公司 | 可前药化抗体、其前药以及使用和制备方法 |
| IL302613B2 (en) | 2017-09-08 | 2025-04-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| CN111630062A (zh) | 2017-11-28 | 2020-09-04 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
| CN111836828B (zh) | 2017-11-28 | 2024-12-20 | 中外制药株式会社 | 包括抗原结合结构域和运送部分的多肽 |
| EP3728326A4 (en) | 2017-12-21 | 2021-12-15 | Amunix Pharmaceuticals, Inc. | SEPARATING SEGMENTS AND BINDING COMPOSITIONS THEREFORE |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| CN110218254B (zh) * | 2018-03-02 | 2020-12-04 | 广西医科大学 | 抗CD3的纳米抗体CD3/Nb25及其制备方法与应用 |
| KR20210020903A (ko) * | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| MA52772A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| US12077577B2 (en) | 2018-05-30 | 2024-09-03 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| TW202519260A (zh) | 2018-07-02 | 2025-05-16 | 美商安進公司 | 抗steap1抗原結合蛋白 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| WO2020084608A1 (en) * | 2018-10-22 | 2020-04-30 | Explore Bio 1 Ltd | Precursor bispecific antibody constructs and methods of use thereof |
| WO2020132291A1 (en) * | 2018-12-19 | 2020-06-25 | City Of Hope | Baff-r bispecific t-cell engager antibody |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| US12516128B2 (en) | 2019-05-14 | 2026-01-06 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| JPWO2020246563A1 (https=) | 2019-06-05 | 2020-12-10 | ||
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc. | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| BR112022019841A2 (pt) | 2020-04-09 | 2022-12-06 | Cytomx Therapeutics Inc | Composições contendo anticorpos ativáveis |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| BR112022025856A2 (pt) | 2020-06-19 | 2023-01-10 | Hoffmann La Roche | Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção |
| KR20230100732A (ko) | 2020-11-04 | 2023-07-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이성 항체의 피하 투여 |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| CN114524878B (zh) * | 2020-11-23 | 2024-08-02 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| TW202304998A (zh) * | 2021-04-06 | 2023-02-01 | 日商武田藥品工業股份有限公司 | 使用限制性條件活化之結合蛋白的治療方法 |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| IL312728A (en) * | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| US20250333487A1 (en) * | 2022-03-25 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| US20240059790A1 (en) * | 2022-04-04 | 2024-02-22 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| CN120569191A (zh) | 2022-11-23 | 2025-08-29 | 乔治亚大学研究基金公司 | 用于增加免疫应答的组合物及其使用方法 |
| CN116724057A (zh) * | 2022-11-28 | 2023-09-08 | 浙江时迈药业有限公司 | 蛋白酶可切割的重组双特异性抗体和组合物及其用途 |
| AU2024346729A1 (en) * | 2023-09-20 | 2026-03-19 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof |
| EP4590715A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| EP4590714A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN100427603C (zh) | 1999-10-04 | 2008-10-22 | 麦迪卡格公司 | 调控外源基因转录的方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| ATE344801T1 (de) | 1999-12-29 | 2006-11-15 | Immunogen Inc | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| US8219149B2 (en) | 2005-06-29 | 2012-07-10 | Nokia Corporation | Mobile communication terminal |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| RU2535992C2 (ru) * | 2007-04-03 | 2014-12-20 | Эмджен Рисерч (Мьюник) Гмбх | Биспецифические связывающие агенты с межвидовой специфичностью |
| WO2008119566A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| KR20110097772A (ko) * | 2008-11-17 | 2011-08-31 | 제넨테크, 인크. | 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제 |
| EP2356131A4 (en) * | 2008-12-08 | 2012-09-12 | Tegopharm Corp | MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| DK2714733T3 (da) * | 2011-05-21 | 2019-05-06 | Macrogenics Inc | Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3 |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| EP2820047B1 (en) * | 2012-03-01 | 2018-04-25 | Amgen Research (Munich) GmbH | Long life polypeptide binding molecules |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| WO2014193973A2 (en) * | 2013-05-28 | 2014-12-04 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
| UA129760C2 (uk) * | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
-
2016
- 2016-04-29 EP EP20184006.3A patent/EP3778640A1/en not_active Withdrawn
- 2016-04-29 JP JP2017557140A patent/JP2018520642A/ja active Pending
- 2016-04-29 HK HK18111551.8A patent/HK1252158A1/zh unknown
- 2016-04-29 WO PCT/US2016/030127 patent/WO2016179003A1/en not_active Ceased
- 2016-04-29 CN CN201680031767.8A patent/CN107709363A/zh active Pending
- 2016-04-29 HK HK18110392.3A patent/HK1250997A1/zh unknown
- 2016-04-29 EP EP16724772.5A patent/EP3288981A1/en not_active Withdrawn
-
2017
- 2017-10-19 US US15/787,922 patent/US20180057593A1/en not_active Abandoned
-
2021
- 2021-09-13 JP JP2021148459A patent/JP2022023031A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520642A5 (https=) | ||
| CN112771066B (zh) | 可活化抗体及其制备和使用方法 | |
| CN111601825B (zh) | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 | |
| CN107849136B (zh) | 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途 | |
| WO2023015169A1 (en) | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof | |
| WO2022170619A1 (en) | Anti-cd3 antibodies and methods of use thereof | |
| CN113993540A (zh) | 用于治疗癌症的一种或多种包含靶向掩蔽i型干扰素(ifna和ifnb)和针对肿瘤抗原的抗体的融合蛋白组合物 | |
| WO2008101234A2 (en) | Anti ganglioside gd3 antibodies and uses thereof | |
| JP7675016B2 (ja) | ムチン－１６に対するヒト化抗体およびそれを使用する方法 | |
| CN113227147B (zh) | 全人源的抗cd30单链抗体及其应用 | |
| US20220233709A1 (en) | Masked Antibody Formulations | |
| AU2006241099A1 (en) | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells | |
| CA2976074A1 (en) | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof | |
| JP7522482B2 (ja) | クローディン１８．２の抗体及びその使用 | |
| JP2025160226A (ja) | Ｆｃ変異を有するヘテロダイマータンパク質 | |
| WO2023060277A1 (en) | Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof | |
| CN114650843A (zh) | 包括fc突变和位点特异性缀合性质的抗体组合物 | |
| Emery et al. | Section Review: Humanised monoclonal antibodies for therapeutic applications | |
| CN119137159A (zh) | 抗cd137抗体和其制备和使用方法 | |
| WO2019173417A1 (en) | Anti-tip-1 antibodies and uses thereof | |
| EP4136122A1 (en) | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof | |
| CN116535509B (zh) | 抗CD79b抗体、其制备方法及其应用 | |
| CN114269784A (zh) | 具有选择性可切割接头的双特异性结合构建体 | |
| JP2024531338A (ja) | 活性化可能インターフェロンポリペプチド及びその使用方法 | |
| CN117529330A (zh) | 用于治疗癌症的包括所掩蔽的I型干扰素(IFNα和IFNβ)的融合蛋白组合物和其方法 |